Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methenamine mandelate - tablet - 500mg, 1000mg - active: methenamine mandelate

Canada - anglais - Health Canada

thuna herbal remedies ltd. - methenamine; sodium bicarbonate; buchu; couch grass; zea mays - liquid - 648mg; 1.296g; 777mg; 777mg; 388mg - methenamine 648mg; sodium bicarbonate 1.296g; buchu 777mg; couch grass 777mg; zea mays 388mg - herbs and natural products

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - methenamine hippurate - oral tablet - 1gram

États-Unis - anglais - NLM (National Library of Medicine)

meda pharmaceuticals - hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - hyoscyamine sulfate 0.12 mg - urelle® is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk - benefit should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

États-Unis - anglais - NLM (National Library of Medicine)

star pharmaceuticals, llc - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - sodium phosphate, monobasic, monohydrate 40.8 mg - phosphasal ™ tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of phosphasal ™ tablets has not been reported and due to the nature of its ingredients, abuse of phosphasal ™ tablets is not expected.

États-Unis - anglais - NLM (National Library of Medicine)

dna labs, inc. - strontium salicylate (unii: ogf9ev99tc) (strontium salicylate - unii:ogf9ev99tc), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), colchicum autumnale bulb (unii: 993qhl78e6) (colchicum autumnale bulb - unii:993qhl78e6), black cohosh (unii: k73e24s6x9) (black cohosh - unii:k73e24s6x9), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw, arnica montana root - unii:mue8y11327), calendula officinalis flowering top (unii: 18e7415pxq) (calendula officinalis flowering top - u - stiffness in joints and muscles.

États-Unis - anglais - NLM (National Library of Medicine)

biocomp pharma - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - phosphasal ® tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of phosphasal ® tablets has not been reported and due to the nature of its ingredients, abuse of

Afrique du Sud - anglais - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - granules - see ingredients - each 4,0 g granules contains citric acid 0,702 g sodium bicarbonate 1,716 g sodium citrate 0,613 g tartaric acid 0,858 g

États-Unis - anglais - NLM (National Library of Medicine)

a.g. marin pharmaceutical - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - uretron d/s tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of uretron d/s tablets has not been reported and due to the nature of its ingredients, abuse of uretron d/s tablets is not expected.

Afrique du Sud - anglais - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - granules - 1716,0 mg, 858,0 mg, 702,0 mg, 613,0 mg - each 4,0 g granules contain: sodium bicarbonate 1716,0 mg, tartaric acid 858,0 mg, citric acid 702,0 mg, sodium citrate 613,0 mg